Abstract
The era of personalized cancer therapy has stared by the recent introduction of cancer genomic medicine to our daily practice.
Tohoku University Hospital established Personalized Medicine Center (P-MEC) in 2017 to promote the development and propagation of genomic medicine for cancer, lifestyle diseases and rare diseases. And also, our hospital and Tohoku Medical Megabank Organization cooperated with each other to start Advanced Research Center for Innovations in Next-Generation Medicine (INGEM) which was established as one of four priority research projects promoted as Designated National University.
In addition, our hospital was certified as Designated Core Hospitals for Cancer Genomic Medicine in February 2019 and has played a great role in leading cancer genomic medicine in Japan. Although there are various issues in clinical use of cancer genomic medicine, such as the way to access for the treatment or the method of corresponding for germline mutation, those have been gradually overcome. Further development is expected.
